Table 1 Patients’ clinical characteristics and laboratory data

Male/Female, n

465/215

76/88

Age (years)

54.9 ± 11.0

56.8 ± 14.8

0.02

IFN therapy N (%)

291 (42.8%)

0 (0.00%)

Habitual alcohol intake N (%)

275 (40.4%)

Body mass index

23.6 ± 3.1

24.0 ± 3.1

0.114

Platelet count (×10⁹/l)

166.7 ± 74.8

228.3 ± 45.1

<0.001

AST (15–46 IU/l)

49.2 ± 39.9

26.4 ± 10.2

<0.001

ALT (0–40 IU/l)

37.7 ± 43.8

23.7 ± 15.1

0.011

GGT (12–73 IU/l)

63.7 ± 105.3

27.2 ± 27.7

<0.001

AFP (0–6.2 IU/l)

7.46 ± 33.9

 1b

126 (18.5%)

 2a

94 (13.8%)

 1b/2a

2 (0.3%)

 Unknown

459 (67.4%)

APRI

1.06 ± 2.72

0.30 ± 0.13

<0.001

FIB4

4.84 ± 12.05

1.33 ± 0.55

<0.001

AST/ALT ratio

2.62 ± 2.80

1.45 ± 1.43

<0.001

GPR

0.58 ± 1.21

0.12 ± 0.12

<0.001

M2BPGi

1.57 ± 2.28

0.38 ± 0.23

<0.001

Fibrosis stage (0 ~ 1/2 ~ 3/4)

437/175/68

155/9/0